| Steven Mark Bloom, MD | |
|
1935 Bluegrass Ave, Suite 200, Louisville, KY 40215-1179 | |
| (502) 895-0040 | |
| (502) 361-4488 |
| Full Name | Steven Mark Bloom |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 40 Years |
| Location | 1935 Bluegrass Ave, Louisville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346224409 | NPI | - | NPPES |
| 64269327 | Medicaid | KY | |
| 300050485 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0107X | Ophthalmology - Retina Specialist | 26932 (Kentucky) | Secondary |
| 207W00000X | Ophthalmology | 26932 (Kentucky) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eye Centers Of Louisville,psc | 4789584921 | 20 |
News Archive
Emisphere Technologies, Inc. today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere's proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles to those of the currently available injectable formulation in healthy postmenopausal women.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.
A new study published in Maternal and Child Health Journal, led by Anna M. Scolese, Master of Public Health student at George Mason University, found that 23.3% of women who experienced intimate partner violence reported their child's school attendance was disrupted due to IPV.
Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.
› Verified 5 days ago
| Entity Name | Eye Centers Of Louisville,psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659385508 PECOS PAC ID: 4789584921 Enrollment ID: O20040113000044 |
News Archive
Emisphere Technologies, Inc. today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere's proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles to those of the currently available injectable formulation in healthy postmenopausal women.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.
A new study published in Maternal and Child Health Journal, led by Anna M. Scolese, Master of Public Health student at George Mason University, found that 23.3% of women who experienced intimate partner violence reported their child's school attendance was disrupted due to IPV.
Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven Mark Bloom, MD 1935 Bluegrass Ave, Suite 200, Louisville, KY 40215-1179 Ph: (502) 895-0040 | Steven Mark Bloom, MD 1935 Bluegrass Ave, Suite 200, Louisville, KY 40215-1179 Ph: (502) 895-0040 |
News Archive
Emisphere Technologies, Inc. today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere's proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles to those of the currently available injectable formulation in healthy postmenopausal women.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.
A new study published in Maternal and Child Health Journal, led by Anna M. Scolese, Master of Public Health student at George Mason University, found that 23.3% of women who experienced intimate partner violence reported their child's school attendance was disrupted due to IPV.
Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.
› Verified 5 days ago
Dr. Brennan P Greene, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1536 Story Ave, The Eye Care Institute Building, Louisville, KY 40206 Phone: 502-589-1500 Fax: 502-589-1556 | |
Theodore M Wandzilak, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 1348 Poplar Level Rd, Louisville, KY 40217 Phone: 502-634-8100 Fax: 502-637-6396 | |
Donald Walter Bennett, OD MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1935 Bluegrass Ave, Suite 200, Louisville, KY 40215 Phone: 502-895-0040 Fax: 502-361-4488 | |
Dr. Mark Cassol, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 800 Zorn Ave, Louisville, KY 40206 Phone: 502-287-4000 | |
Lawrence Tenkman, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1935 Bluegrass Ave, Suite 200, Louisville, KY 40215 Phone: 502-895-0040 Fax: 502-361-4488 | |
Dr. Jacob Jones Yunker, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3810 Springhurst Blvd, Suite 100, Louisville, KY 40241 Phone: 502-897-9881 Fax: 502-897-9824 | |
Christopher J Compton, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 301 E Muhammad Ali Blvd, Louisville, KY 40202 Phone: 502-852-1665 |